PCRX Q1 2022 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$158M+32.7% YoY

Gross Profit

$122M77.2% margin

Operating Income

$17M11.0% margin

Net Income

$7M4.3% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

-0.8%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$23M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$1.2B

Stockholders' Equity

$710M

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$158M	$119M	+32.7%
Gross Profit	$122M	$88M	+39.1%
Operating Income	$17M	$19M	-10.5%
Net Income	$7M	$10M	-34.1%

Revenue Segments

Product

$157M50%

EXPAREL/bupivacaine liposome injectable suspension

$129M41%

ZILRETTA

$24M8%

Bupivacaine Liposome Injectable Suspension

$2M0%